查看購物車
  • Simplified Chinese
  • English
2021-2031年亞太臨床試驗市場報告：範圍、細分、動態和競爭分析
市場調查報告書
商品編碼
1871412

2021-2031年亞太臨床試驗市場報告：範圍、細分、動態和競爭分析

Asia Pacific Clinical Trials Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 129 Pages | 訂單完成後即時交付

價格

預計亞太地區臨床試驗市場將顯著成長，到 2031 年將達到約 167.6221 億美元，高於 2023 年的 93.3952 億美元，在此期間的年複合成長率(CAGR) 為 7.6%。

執行摘要和市場分析

亞太地區被公認為臨床試驗成長最快的市場，涵蓋中國、日本、印度、韓國、澳洲、印尼、新加坡、馬來西亞等國家。值得注意的是，澳洲、印度和韓國等國家由於醫療保健產業的進步，蓄勢待發，可望快速成長。這些國家的政府積極推動臨床試驗，加上慢性病盛行率不斷上升以及公眾對臨床試驗的認知度不斷提高，預計將在不久的將來為市場參與者創造巨大的機會。

市場區隔分析

亞太地區臨床試驗市場可依研究設計、適應症及階段類型進行細分：

  • 研究設計：市場分為干涉性試驗和擴大准入試驗，到 2023 年，干預性試驗將佔據市場佔有率的主導地位。
  • 適應症：主要領域包括自體免疫/發炎、疼痛管理、腫瘤、神經系統疾病、糖尿病、肥胖、代謝性疾病、心血管疾病等。 2023年，腫瘤領域佔據主導地位。
  • 階段類型：市場分為 I 期、II 期和 III 期試驗，其中 II 期在 2023 年佔據最大的市場佔有率。

市場展望

研究在製藥、生物製藥和醫療器材產業中發揮著至關重要的作用，它促進了具有巨大醫療和商業潛力的新型治療方案的開發。製藥業是全球研發投入最高的產業之一，致力於提高療效和效率，以滿足患者的需求。藥品成本的不斷上漲促使製藥公司加大研發投入，以實現成本目標。過去十年，新藥的年度獲批率持續成長，研發支出對於發現、測試和生產新產品以及確保符合監管要求至關重要。

根據美國藥品研究與製造商協會（PhRMA）成員公司2021年發布的報告，前15位的製藥公司在研發方面共投入1,330億美元，其中約44%用於臨床試驗。這些公司與醫院的合作正在推動包括免疫系統疾病在內的多種疾病療法的研發。例如，武田製藥於2021年6月啟動了ADVANCE-1試驗，旨在評估HYQVIA治療慢性發炎性脫髓鞘性多發性神經根神經病變（CIDP）的療效。

國家概況

亞太臨床試驗市場涵蓋中國、日本、印度、澳洲、韓國、印尼、馬來西亞、新加坡等主要國家。 2023年，中國憑藉其成熟的製藥產業、不斷成長的研發投入、成本降低帶來的臨床試驗數量激增以及完善的監管框架，成為亞太地區最大的市場。作為全球第二大醫藥市場，中國龐大的人口基數以及傳染病和非傳染性疾病發病率的不斷上升，正推動其醫藥產業的蓬勃發展，使其成為開展臨床試驗的理想之地。

中國對藥物臨床試驗的大力支持加速了新藥研發過程。 《中國新藥臨床試驗進展年度報告》顯示，註冊臨床試驗數量穩定成長，從2021年的3,358項增加至2023年的4,300項。此外，500種生物製品獲批上市，其中腫瘤、皮膚病和內分泌是重要的治療領域。中國也成為國際製藥公司尋求縮短產品研發週期和降低研發成本的理想研發外包目的地。西方公司參與中國臨床試驗的數量也從2010年的每年約100項增加至2021年的約350項。

近年來，中國醫藥產業專注於研發創新藥物。例如，2021年，紐安斯製藥與維羅納製藥合作，在大中華區開發恩西芬特林，並於2023年4月啟動了該藥物作為慢性阻塞性肺病維持治療的III期臨床試驗。

公司簡介

臨床試驗市場的主要參與者包括QVIA Holdings Inc、Parexel International Corp、IXICO Plc、Charles River Laboratories、ICON Plc、藥明康德、SGS SA、Syneos Health、Thermo Fisher Scientific、Laboratory Corp of America、CliniRx Research、Caidya、Oracle CorpRO、Medpace和SI Clinpharm。這些公司正透過擴張、產品創新以及併購等多種策略來增強市場佔有率並提供創新解決方案。

目錄

第1章：引言

第2章：執行概要

  • 關鍵見解
  • 市場吸引力

第3章：研究方法

  • 二手研究
  • 初步研究
    • 假設的提出：
    • 宏觀經濟因素分析：
    • 發展基礎數字：
    • 數據三角測量：
    • 國家層面資料：
  • 假設和局限性

第4章：亞太地區臨床試驗市場概況

  • 概述
  • PEST分析
  • 生態系分析
  • 價值鏈中的供應商列表

第5章：亞太臨床試驗市場－主要市場動態

  • 亞太臨床試驗市場—主要市場動態
  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 未來趨勢

駕駛員和安全帶的影響：

第6章：亞太臨床試驗市場分析

  • 2021-2031年亞太臨床試驗市場收入
  • 亞太臨床試驗市場預測分析

第7章：亞太地區臨床試驗市場分析－依研究設計分類

  • 干預性試驗
  • 擴大使用試驗

第8章：亞太地區臨床試驗市場分析－依適應症分類

  • 自體免疫/炎症
  • 疼痛管理
  • 腫瘤學
  • 神經系統疾病
  • 糖尿病
  • 肥胖
  • 代謝紊亂
  • 心血管
  • 其他

第9章：亞太地區臨床試驗市場分析－依階段類型分類

  • 第一階段
  • 第二階段
  • 第三階段

第10章：亞太臨床試驗市場—國家分析

  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 印尼
    • 馬來西亞
    • 新加坡
    • 亞太其他地區

第11章：競爭格局

  • 關鍵參與者熱力圖分析
  • 公司定位與集中度

第12章：行業概況

  • 概述
  • 市場拓展計劃
  • 夥伴關係與合作
  • 其他進展

第13章：公司簡介

  • IQVIA Holdings Inc
  • Parexel International Corp
  • IXICO Plc
  • Charles River Laboratories International Inc
  • ICON Plc
  • WuXi AppTec Co Ltd
  • SGS SA
  • Syneos Health Inc
  • SIRO Clinpharm Pvt Ltd
  • Thermo Fisher Scientific Inc
  • Laboratory Corp of America Holdings
  • CliniRx Research Private Limited
  • Caidya
  • Oracle Corp
  • Medpace Holdings Inc

第14章：附錄

Product Code: BMIRE00028988

The Asia Pacific clinical trials market is projected to grow significantly, reaching approximately US$ 16,762.21 million by 2031, up from US$ 9,339.52 million in 2023, reflecting a compound annual growth rate (CAGR) of 7.6% during this period.

Executive Summary and Market Analysis

The Asia Pacific (APAC) region is recognized as the fastest-growing market for clinical trials, encompassing countries such as China, Japan, India, South Korea, Australia, Indonesia, Singapore, Malaysia, and others. Notably, nations like Australia, India, and South Korea are poised for growth due to advancements in their healthcare sectors. Governments in these countries are actively promoting clinical trials, which, combined with the rising prevalence of chronic diseases and increased awareness of clinical trials, is expected to create substantial opportunities for market participants in the near future.

Market Segmentation Analysis

The Asia Pacific clinical trials market can be segmented based on study design, indications, and phase type:

  • Study Design: The market is divided into interventional trials and expanded access trials, with interventional trials dominating the market share in 2023.
  • Indications: Key segments include autoimmune/inflammation, pain management, oncology, neurological disorders, diabetes, obesity, metabolic disorders, cardiovascular diseases, and others. Oncology was the leading segment in 2023.
  • Phase Type: The market is categorized into phase I, phase II, and phase III trials, with phase II holding the largest market share in 2023.

Market Outlook

Research plays a crucial role in the pharmaceutical, biopharmaceutical, and medical device industries, facilitating the development of new therapeutic solutions with significant medical and commercial potential. The pharmaceutical sector is among the most research and development (R&D)-intensive industries globally, striving for enhanced effectiveness and efficiency in meeting patient needs. The rising costs of medications have prompted pharmaceutical companies to invest heavily in R&D to achieve their cost targets. Over the past decade, the annual approval rate of new drugs has increased, with R&D expenditures being vital for discovering, testing, and producing new products, as well as ensuring regulatory compliance.

According to a 2021 report by PhRMA Member Companies, the top 15 pharmaceutical companies collectively invested US$ 133 billion in R&D, with approximately 44% allocated to clinical trials. Collaborations between these companies and hospitals are driving the development of treatments for various diseases, including immunological disorders. For instance, in June 2021, Takeda initiated the ADVANCE-1 trial to evaluate HYQVIA for treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Country Insights

The Asia Pacific clinical trials market includes key countries such as China, Japan, India, Australia, South Korea, Indonesia, Malaysia, Singapore, and others. China emerged as the largest market in 2023, driven by its established pharmaceutical sector, increased R&D spending, a growing number of clinical trials due to lower costs, and supportive regulatory frameworks. With the world's second-largest pharmaceutical market, China's vast population and rising incidence of both communicable and non-communicable diseases are propelling the growth of its pharmaceutical industry, making it a prime location for clinical trials.

China's commitment to supporting drug clinical trials has accelerated new drug development. The Annual Report on the Progress of Clinical Trials for New Drug Registration in China indicates a steady increase in registered clinical trials, from 3,358 in 2021 to 4,300 in 2023. Additionally, 500 biological products were approved, with oncology, dermatology, and endocrinology being significant therapeutic areas. The country has also become an attractive R&D outsourcing destination for international pharmaceutical firms seeking to reduce product timelines and costs. The involvement of Western companies in clinical trials in China has risen from about 100 trials per year in 2010 to approximately 350 in 2021.

In recent years, the Chinese pharmaceutical industry has focused on R&D to innovate new drugs. For example, in 2021, Nuance Pharma entered a partnership with Verona Pharma for the development of ensifentrine in Greater China, and in April 2023, they initiated a Phase III trial for this drug as a maintenance treatment for chronic obstructive pulmonary disease.

Company Profiles

Key players in the clinical trials market include QVIA Holdings Inc, Parexel International Corp, IXICO Plc, Charles River Laboratories, ICON Plc, WuXi AppTec, SGS SA, Syneos Health, Thermo Fisher Scientific, Laboratory Corp of America, CliniRx Research, Caidya, Oracle Corp, Medpace, and SIRO Clinpharm. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative solutions.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:
  • 3.3 Assumptions and Limitations

4. Asia Pacific Clinical Trials Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
  • 4.4 List of Vendors in the Value Chain

5. Asia Pacific Clinical Trials Market - Key Market Dynamics

  • 5.1 Asia Pacific Clinical Trials Market - Key Market Dynamics
  • 5.2 Market Drivers
  • 5.3 Market Restraints
  • 5.4 Market Opportunities
  • 5.5 Future Trends

Impact of Drivers and Restraints:

6. Asia Pacific Clinical Trials Market - Analysis

  • 6.1 Asia Pacific Clinical Trials Market Revenue (US$ Million), 2021-2031
  • 6.2 Asia Pacific Clinical Trials Market Forecast Analysis

7. Asia Pacific Clinical Trials Market Analysis - by Study Design

  • 7.1 Interventional Trials
    • 7.1.1 Overview
    • 7.1.2 Interventional Trials: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.2 Expanded Access Trials
    • 7.2.1 Overview
    • 7.2.2 Expanded Access Trials: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Asia Pacific Clinical Trials Market Analysis - by Indications

  • 8.1 Autoimmune/Inflammation
    • 8.1.1 Overview
    • 8.1.2 Autoimmune/Inflammation: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.2 Pain Management
    • 8.2.1 Overview
    • 8.2.2 Pain Management: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.3 Oncology
    • 8.3.1 Overview
    • 8.3.2 Oncology: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.4 Neurological Disorders
    • 8.4.1 Overview
    • 8.4.2 Neurological Disorders: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.5 Diabetes
    • 8.5.1 Overview
    • 8.5.2 Diabetes: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.6 Obesity
    • 8.6.1 Overview
    • 8.6.2 Obesity: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.7 Metabolic Disorders
    • 8.7.1 Overview
    • 8.7.2 Metabolic Disorders: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.8 Cardiovascular
    • 8.8.1 Overview
    • 8.8.2 Cardiovascular: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.9 Others
    • 8.9.1 Overview
    • 8.9.2 Others: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Asia Pacific Clinical Trials Market Analysis - by Phase Type

  • 9.1 Phase I
    • 9.1.1 Overview
    • 9.1.2 Phase I: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.2 Phase II
    • 9.2.1 Overview
    • 9.2.2 Phase II: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.3 Phase III
    • 9.3.1 Overview
    • 9.3.2 Phase III: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Asia Pacific Clinical Trials Market - Country Analysis

  • 10.1 Asia Pacific
    • 10.1.1 Asia Pacific Clinical Trials Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 Asia Pacific Clinical Trials Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 China: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.2.1 China: Asia Pacific Clinical Trials Market Share - by Study Design
        • 10.1.1.2.2 China: Asia Pacific Clinical Trials Market Share - by Indications
        • 10.1.1.2.3 China: Asia Pacific Clinical Trials Market Share - by Phase Type
      • 10.1.1.3 Japan: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.3.1 Japan: Asia Pacific Clinical Trials Market Share - by Study Design
        • 10.1.1.3.2 Japan: Asia Pacific Clinical Trials Market Share - by Indications
        • 10.1.1.3.3 Japan: Asia Pacific Clinical Trials Market Share - by Phase Type
      • 10.1.1.4 India: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.4.1 India: Asia Pacific Clinical Trials Market Share - by Study Design
        • 10.1.1.4.2 India: Asia Pacific Clinical Trials Market Share - by Indications
        • 10.1.1.4.3 India: Asia Pacific Clinical Trials Market Share - by Phase Type
      • 10.1.1.5 Australia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.5.1 Australia: Asia Pacific Clinical Trials Market Share - by Study Design
        • 10.1.1.5.2 Australia: Asia Pacific Clinical Trials Market Share - by Indications
        • 10.1.1.5.3 Australia: Asia Pacific Clinical Trials Market Share - by Phase Type
      • 10.1.1.6 South Korea: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.6.1 South Korea: Asia Pacific Clinical Trials Market Share - by Study Design
        • 10.1.1.6.2 South Korea: Asia Pacific Clinical Trials Market Share - by Indications
        • 10.1.1.6.3 South Korea: Asia Pacific Clinical Trials Market Share - by Phase Type
      • 10.1.1.7 Indonesia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.7.1 Indonesia: Asia Pacific Clinical Trials Market Share - by Study Design
        • 10.1.1.7.2 Indonesia: Asia Pacific Clinical Trials Market Share - by Indications
        • 10.1.1.7.3 Indonesia: Asia Pacific Clinical Trials Market Share - by Phase Type
      • 10.1.1.8 Malaysia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.8.1 Malaysia: Asia Pacific Clinical Trials Market Share - by Study Design
        • 10.1.1.8.2 Malaysia: Asia Pacific Clinical Trials Market Share - by Indications
        • 10.1.1.8.3 Malaysia: Asia Pacific Clinical Trials Market Share - by Phase Type
      • 10.1.1.9 Singapore: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.9.1 Singapore: Asia Pacific Clinical Trials Market Share - by Study Design
        • 10.1.1.9.2 Singapore: Asia Pacific Clinical Trials Market Share - by Indications
        • 10.1.1.9.3 Singapore: Asia Pacific Clinical Trials Market Share - by Phase Type
      • 10.1.1.10 Rest of APAC: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.10.1 Rest of APAC: Asia Pacific Clinical Trials Market Share - by Study Design
        • 10.1.1.10.2 Rest of APAC: Asia Pacific Clinical Trials Market Share - by Indications
        • 10.1.1.10.3 Rest of APAC: Asia Pacific Clinical Trials Market Share - by Phase Type

11. Competitive Landscape

  • 11.1 Heat Map Analysis by Key Players
  • 11.2 Company Positioning and Concentration

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Market Initiative
  • 12.3 Partnerships and Collaborations
  • 12.4 Other Developments

13. Company Profiles

  • 13.1 IQVIA Holdings Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Parexel International Corp
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 IXICO Plc
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Charles River Laboratories International Inc
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 ICON Plc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 WuXi AppTec Co Ltd
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 SGS SA
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Syneos Health Inc
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 SIRO Clinpharm Pvt Ltd
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Thermo Fisher Scientific Inc
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Laboratory Corp of America Holdings
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments
  • 13.12 CliniRx Research Private Limited
    • 13.12.1 Key Facts
    • 13.12.2 Business Description
    • 13.12.3 Products and Services
    • 13.12.4 Financial Overview
    • 13.12.5 SWOT Analysis
    • 13.12.6 Key Developments
  • 13.13 Caidya
    • 13.13.1 Key Facts
    • 13.13.2 Business Description
    • 13.13.3 Products and Services
    • 13.13.4 Financial Overview
    • 13.13.5 SWOT Analysis
    • 13.13.6 Key Developments
  • 13.14 Oracle Corp
    • 13.14.1 Key Facts
    • 13.14.2 Business Description
    • 13.14.3 Products and Services
    • 13.14.4 Financial Overview
    • 13.14.5 SWOT Analysis
    • 13.14.6 Key Developments
  • 13.15 Medpace Holdings Inc
    • 13.15.1 Key Facts
    • 13.15.2 Business Description
    • 13.15.3 Products and Services
    • 13.15.4 Financial Overview
    • 13.15.5 SWOT Analysis
    • 13.15.6 Key Developments

14. Appendix

  • 14.1 About Us
  • 14.2 List of Abbreviations

List Of Tables

  • Table 1. Asia Pacific Clinical Trials Market Segmentation
  • Table 2. List of Vendors
  • Table 3. Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Table 4. Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Study Design
  • Table 5. Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 6. Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Phase Type
  • Table 7. Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 8. China: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 9. China: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 10. China: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 11. Japan: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 12. Japan: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 13. Japan: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 14. India: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 15. India: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 16. India: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 17. Australia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 18. Australia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 19. Australia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 20. South Korea: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 21. South Korea: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 22. South Korea: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 23. Indonesia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 24. Indonesia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 25. Indonesia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 26. Malaysia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 27. Malaysia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 28. Malaysia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 29. Singapore: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 30. Singapore: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 31. Singapore: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 32. Rest of APAC: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 33. Rest of APAC: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 34. Rest of APAC: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 35. List of Abbreviations

List Of Figures

  • Figure 1. Asia Pacific Clinical Trials Market Segmentation - Country
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Asia Pacific Clinical Trials Market Revenue (US$ Million), 2021-2031
  • Figure 5. Asia Pacific Clinical Trials Market Share (%) - by Study Design (2023 and 2031)
  • Figure 6. Interventional Trials: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 7. Expanded Access Trials: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 8. Asia Pacific Clinical Trials Market Share (%) - by Indications (2023 and 2031)
  • Figure 9. Autoimmune/Inflammation: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 10. Pain Management: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 11. Oncology: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 12. Neurological Disorders: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 13. Diabetes: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 14. Obesity: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 15. Metabolic Disorders: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 16. Cardiovascular: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 17. Others: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 18. Asia Pacific Clinical Trials Market Share (%) - by Phase Type (2023 and 2031)
  • Figure 19. Phase I: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 20. Phase II: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 21. Phase III: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. Asia Pacific Clinical Trials Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 23. China: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 24. Japan: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 25. India: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 26. Australia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 27. South Korea: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 28. Indonesia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 29. Malaysia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 30. Singapore: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 31. Rest of APAC: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 32. Heat Map Analysis by Key Players
  • Figure 33. Company Positioning and Concentration